PRIMA: 36-month clinical trial results
Science Corporation reported sustained vision improvements at 36 months in patients evaluated in the PRIMAvera trial of its retinal implant.
TALKS · RESEARCH · CONVERSATIONS
Selected conversations, research releases, and updates from the work.
Science Corporation reported sustained vision improvements at 36 months in patients evaluated in the PRIMAvera trial of its retinal implant.
A conversation with Foresight Institute about the development of biohybrid neural interfaces.
Speaking at San Francisco Deep Tech Week, hosted by PsyMed Ventures and E11 Bio.
Science’s progress on optogenetic gene and cell therapies, presented at Campus Biotech.
An interview with Ira Pastor on Progress, Potential, and Possibilities.
Our WAChR work expands the sensitivity of optogenetic tools. With Alex Naka and the Science team.
A panel at the Center for Neuroengineering and Medicine’s annual research symposium.
A first demonstration of transmitting information to the brain through a cortical biohybrid implant.
Combining optogenetics and an engineered visual prosthesis.
Berkeley News on our work developing precise optical control of neural ensembles.